Cytomegalovirus (CMV) infection during the transient immunodeficiency after bone marrow transplantation (BMT) develops into
within the donor cell population distracted the donor T cells from protecting recipient tissues and that protection in the chimeras was therefore primarily based on recipient T cells. As a consequence, T-cell chimerism after BMT should give a positive prognosis with respect to control of CMV.
Cytomegaloviruses (CMV) are kept under tight immune control (for reviews, see references 22 and 23). As a consequence, acute CMV infection is resolved rapidly and does not result in disease unless the host is immunologically immature or immunocompromised. Bone marrow (BM) transplantation (BMT) as a therapy of hematological malignancies is associated with a transient immunodeficiency. Accordingly, during the period of immunocompromise, transmission of donor-type CMV with the transplant as well as recurrence of CMV from latency established within the organs of the transplantation recipient both entail a risk for destructive virus replication in tissues resulting in multiple-organ CMV disease (16) . In BMT recipients, CMV-induced interstitial pneumonia is a frequent and endangering manifestation of CMV disease (11, 27) . However, CMV infection does not inevitably result in fatal disease. It appears that CD8 T-cell reconstitution is the decisive parameter in the control of CMV after BMT. Clinical data have shown that both efficient reconstitution of CD8 T cells (41) and supplementation of antiviral CD8 T cells by preemptive cytoimmunotherapy with T-cell lines (42, 50) correlate with a reduced risk of human CMV disease, whereas combined in vivo-ex vivo T-cell depletion, intended as a prophylaxis against graft-versus-host (GvH) disease, accidentally resulted in an increased incidence of CMV infections in BMT patients (14) . Aspects of these clinical problems can be approached experimentally in a murine model of BMT and concurrent infection with murine CMV (for an overview, see reference 35). Specifically, depletion of CD8 T cells, but not of CD4 T cells, performed in vivo during the phase of reconstitution after BMT abolished the development of protective antiviral immunity, with an inevitably lethal outcome (34, 47) resulting from multiple-organ pathology (34) , including BM aplasia (29, 30) . Likewise, an insufficient endogenous reconstitution was successfully supplemented by experimental adoptive cytoimmunotherapy with antiviral CD8 T cells. Again, CD4 T cells were not effective (36, 37, 39, 47) . Altogether, clinical data on human CMV infection and experimental data from the murine model have so far been concordant and have identified CD8 T cells as the principal effectors controlling CMV infections after BMT.
These findings imply that all conditions which lower the efficacy of CD8 T-cell reconstitution will increase the risk for progression of asymptomatic CMV infection to fatal CMV disease. Histoincompatibility between graft and recipient is a factor likely to negatively influence the restoration of antiviral immunity. Accordingly, even though cases of severe human CMV disease have been reported also after autologous BMT (27, 40) , the incidence of CMV-related complications is generally higher after histoincompatible BMT (51) . In clinical BMT, donor and recipient are usually matched in major histocompatibility complex (MHC) class II molecules, whereas differences in minor histocompatibility loci and in MHC class I loci are tolerated if unavoidable. Complications caused in the CMV-infected recipient by histoincompatibility may include (i) an impaired engraftment of transplanted cells in the recipient BM stroma, (ii) an immunological GvH response as well as a host-versus-graft (HvG) response directed against the foreign minor or major histocompatibility molecules, and (iii) a lack of antiviral T-cell control resulting from an inappropriate repertoire of viral antigenic peptides presented by infected tissue cells of the transplantation recipient.
In a first attempt to dissect these possibilities, we have established a murine model of experimental BMT (44) , respectively. Depending on the choice of donor and recipient for the BMT, immunogenetical GvH and HvG conditions can be studied separately (35) . Work presented herein focuses on the HvG setting with BALB/c as the donor strain and the mutant as the recipient. Hence, after incomplete depletion of hematopoietic cells of the recipients, this model entails a risk for graft rejection caused by a recipient response directed against the donor MHC class I molecule L (18, 38) , is confined to donor-derived hematopoietic cells and their progeny, whereas the parenchymal and stromal sites of cytocidal infection (34) lack L d as the prevailing peptide presenter. The aim of the study was to investigate the influence of this particular MHC class I disparity on the control of murine CMV after BMT. were used at the age of 8 weeks as donors and recipients, respectively, of BM cells (BMC). For hematoablative conditioning, recipients were total-body ␥ irradiated with a dose of 6 Gy delivered by a 137 Cs ␥-ray source. Donor femoral and tibial BMC were isolated by flushing medium through the bone shafts (30) and were depleted of contaminating intravascular and sinusoidal CD8 T cells (Ͻ2% in normal BALB/c BM) by three cycles of treatment with rat anti-murine CD8 monoclonal antibody (MAb) clone YTS 169.4 (7) and magnetic beads coated with sheep anti-rat immunoglobulin (Ig) antibody (Ab) (Dynabeads M-450; Dynal, Oslo, Norway) at a bead-to-cell ratio of 2:1. The indicated numbers of BMC were infused intravenously into the tail veins of recipients about 6 h after irradiation. Survival rates were determined for groups of 20 recipients by daily monitoring. For adoptive cell transfer, indicator recipients were irradiated with 6 Gy and received the indicated numbers of unseparated, T-cell subset-depleted, or sorted pulmonary infiltrate lymphocytes in place of BMC. The in vitro depletion of CD8 and CD4 T cells was achieved by two cycles of treatment with the relevant MAbs and complement (47) . Recipients were infected with 10 5 PFU of purified murine CMV (25) strain Smith (ATCC VR-194), injected subcutaneously in the left hind footpad about 2 h after BMT or T-cell transfer.
MATERIALS AND METHODS

HvG
Determination of virus titers in organs. The titer of infectious virus in organs was determined by a plaque assay performed with centrifugal enhancement of infectivity as described previously (25) . In brief, organs were frozen and thawed to disrupt the cells and were homogenized by passage through a steel mesh. Appropriate dilutions of the homogenate were used in duplicate to infect permissive murine embryonic fibroblasts grown to near-confluent monolayers in flat-bottomed 48-well Falcon plates. Infection was performed at a centrifugal force of 1,000 ϫ g for 30 min at 20°C. A methylcellulose overlay medium served to prevent the formation of secondary plaques. Primary plaques were counted after an incubation of the cultures for 4 to 5 days. The virus titers represent PFU per organ and are indexed as PFU* to indicate centrifugal enhancement.
Two-color immunohistochemistry for the analysis of tissue infection and Tcell infiltration. Livers were fixed with phosphate-buffered saline (PBS; pH 7.4) containing 4% (vol/vol) formalin. The tissue was then processed by standard procedures for paraffin embedding. Sections of 2 m were dewaxed in xylene and subjected to two-color immunohistochemistry essentially as described recently (18) . In brief, T cells expressing CD3ε were labeled by an incubation of the sections for 1 h with a rat IgG1 MAb, clone CD3-12. Rat IgG1 (catalog no. 344 71A; Pharmingen, San Diego, Calif.) was used for the isotype control. The staining was performed by using a biotinylated goat anti-rat Ig Ab and the avidin-biotin-peroxidase complex with diaminobenzidine tetrahydrochloride as the substrate. The staining was enhanced by ammonium nickel sulfate hexahydrate, resulting in a black precipitate. The viral IE1 protein pp89 (21) was labeled by incubation for 1 h with MAb CROMA 101 (murine IgG1), followed by staining with rabbit anti-mouse Ig Ab and the alkaline phosphatase-anti-alkaline phosphatase (APAAP) complex with new fuchsin as the substrate, yielding a red precipitate. The isotype control was performed with mouse IgG1 (catalog no. X-0931; Dako, Hamburg, Germany). Counterstaining was done with hematoxylin. Infected cells as well as liver-infiltrating cells were counted for representative, randomly selected 10-mm 2 areas of tissue. Detection of viral DNA by ISH. Deparaffinized sections of liver and spleen were subjected to in situ hybridization (ISH) as described previously (29) . In essence, viral DNA accumulated in an intranuclear inclusion body in infected cells was stained with a digoxigenin-11-dUTP-labeled probe of 1,534 bp specific for the murine CMV gB gene. Labeling was performed with alkaline phosphatase-conjugated antidigoxigenin Ab with new fuchsin as the substrate. Counterstaining was done with hematoxylin.
Isolation of lymphocytes from pulmonary infiltrates. Lymphocytes were isolated from the lung parenchyma by using a modification (18) of the method described by Holt et al. (17) . Mice were lethally anesthetized by inhalation of carbon dioxide. For removing intravascular leukocytes, the vascular bed of the lungs was perfused with 5 to 10 ml of PBS devoid of Ca 2ϩ and Mg 2ϩ and containing heparin (10 U/ml). Alveolar leukocytes were removed by bronchoalveolar lavage. The lungs were then excised, and trachea, bronchi, bronchioles, and peritracheal as well as hilar lymph nodes were discarded. The lung parenchyma was minced, and a single-cell suspension was prepared by collagenaseDNase digestion. Specifically, tissue pooled from several lungs was incubated under permanent stirring at a volume of 5 ml per lung for 1 h at 37°C in high-glucose Dulbecco's modified Eagle's medium (catalog no. 41965-039; Gibco BRL, Eggenstein, Germany) supplemented with 10% fetal calf serum, penicillin, and streptomycin and containing type I collagenase (200 U/ml; Biochrom, Berlin, Germany) and type I DNase (50 g/ml; DN-25; Sigma). Cells were washed and resuspended in RPMI (catalog no. 31870-025; Gibco BRL) supplemented as described previously (18) . Lymphocytes were enriched by density gradient centrifugation for 30 min at 760 ϫ g on Ficoll (1.077 g/ml; Sigma).
Cytofluorometric analysis. Cell surface antigen expression was analyzed by fluorescence-activated cell sorting (FACS) with a FACSort (Becton Dickinson, San Jose, Calif.), using CellQuest software (Becton Dickinson) for data processing. Compensation of the overlap in the emission spectra of fluorescent dyes was done throughout. For all measurements, a threshold was set in the forward scatter (FSC)-versus-side scatter (SSC) plot to exclude events of the size of erythrocytes and to exclude dead cells. If not indicated otherwise, a lymphocyte gate was set in the FSC-versus-SSC plot to exclude macrophages and residual granulocytes from analysis.
Spleen (iii) Determination of CD8/CD4 ratios. Three-color labeling was performed with FITC-conjugated rat anti-mouse CD8a MAb (IgG2a; clone 53-6.7, catalog no. 1353; Becton Dickinson), PE-conjugated hamster anti-mouse TCR ␣/␤ MAb, and duochrome-conjugated rat anti-mouse CD4 MAb. The analysis of CD8 and CD4 expression was restricted to ␣/␤ T cells by setting an electronic gate on signals with positive PE fluorescence.
Sorting of donor-derived and recipient-derived CD8 T cells. CD8 T cells of donor or recipient origin were preparatively purified by a combination of positive immunomagnetic selection and cytofluorometric cell sorting. Cell washing steps and incubations were performed with FACS buffer devoid of NaN 3 .
(i) Immunomagnetic enrichment of CD8 T cells. Ficoll gradient-enriched lymphocytes derived from pulmonary infiltrates of BMT chimeras were first incubated with blocking solution devoid of NaN 3 (ca. 3 ϫ 10 7 cells in 90 l) and 10 l of superparamagnetic 50-nm-diameter beads (MicroBeads, catalog no. 481-01; Miltenyi Biotec Systems, Bergisch-Gladbach, Germany) and then passed through a magnetic separation column (MiniMacs separation unit, column type MS, catalog no. 422-01; Miltenyi Biotec Systems) to remove debris and cells binding nonspecifically to the magnetic beads. Effluent cells were collected, incubated with beads (10 l per ca. 2 ϫ 10 7 cells in 90 l of FACS buffer) that were conjugated with rat MAb (IgG2a; clone 53-6.7) directed against mouse CD8a (MicroBeads, catalog no. 494-01; Miltenyi Biotec Systems), and separated in the magnetic column. It should be noted that the load of beads per cell is below the threshold critical for functional blocking of CD8 molecules. The CD8-negative effluent cells were discarded. The positively selected CD8-positive cells were recovered by elution with FACS buffer after disconnection of the magnetic field. The purity of the cells was determined by two-color cytofluorometric analysis. For this, an aliquot of the cell yield was labeled with mouse anti-mouse H-2L d MAb (IgG2a; clone 30-5-75), FITCconjugated goat anti-mouse IgG2a Ab, and PE-conjugated rat anti-mouse CD8a MAb (clone 53-6.7, catalog no. 1271 237; Boehringer, Mannheim, Germany).
(ii) Cytofluorometric cell sorting. The CD8 T cells derived from the immunomagnetic sorting were labeled indirectly with mouse anti-mouse H-2L d MAb and FITC-conjugated goat anti-mouse IgG2a Ab. Sorting was performed at a sort rate of ca. 10,000 cells/min with a FACSort equipped with a cell concentrator module (Becton Dickinson). The purity of the sorted cell populations was determined by two-color analytic cytofluorometry. For this, aliquots of the sorted cells were additionally labeled with PE-conjugated hamster anti-mouse TCR ␣/␤ MAb. Further aliquots were used to determine the cytolytic activity. Finally, the remaining cells were used for adoptive transfer.
Cytolytic assays. For measuring the lytic activity of cytolytic T lymphocytes (CTL), standard 4-h 51 Cr release assays were performed at the indicated effector/target cell ratios with a constant number (10 3 ) of 51 Cr-labeled target cells and graded numbers of effector cells in 0.2-ml round-bottomed 96-microwell plates. 
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Throughout, reported cytolytic activity represents the mean percentage of specific 51 Cr release from three replicate microcultures. (i) Antigen-independent assessment of cytolytic activity by TCR ␣/␤-redirected lysis. The strategy of redirected lysis (24) was used to measure the total cytolytic activity of CTL populations. For this, Fc receptor-expressing P815 cells (ATCC TIB-64; mastocytoma cell line derived from the mouse strain DBA/2; H-2 d ) were armed with Abs by incubation for 15 min at 20°C with an optimized dose of hamster MAb (IgG) specific for murine TCR ␣/␤ (clone H57-597, catalog no. 01301D; Dianova) before use as target cells.
(ii) Assessment of HvG-reactive cytolytic activity. CTL activity directed against L d was monitored with the L d -expressing target cells P815 and the P815-derived transfectants P815-B7 and P815-Fas, expressing B7-1 (CD80) (1, 2) and Fas (CD95) (43) , respectively. The transfectant cell lines were propagated in selection media containing 1 mg of Geneticin (G418) per ml and 1 mM L-histidinol, respectively. The expression of CD80 and CD95 was verified by cytofluorometric analysis using FITC-conjugated mouse anti-human B7-1 MAb (clone BB1, catalog no. 33514; Dianova) and FITC-conjugated hamster anti-mouse Fas MAb (clone Jo2, catalog no. 15404D; Dianova), respectively.
RESULTS
Establishment of T-cell chimerism after MHC-disparate
BMT following incomplete lymphohematoablation. By definition, recipients of a nonautologous BMT become chimeric in that their own hematopoietic cells are replaced by donor-derived hematopoietic cells, whereas stromal and parenchymal cells of all tissues remain of recipient genotype. It is known that incomplete hematoablation of BMT recipients can lead to a donor-recipient chimerism also within the population of hematopoietic cells and their progeny. This situation is referred to as mixed chimerism, as opposed to the complete chimerism established after complete hematoablation of the recipients followed by lymphohematopoietic repopulation exclusively with donor-derived cells. Notably, a stable mixed chimerism is associated with donor-specific central transplantation tolerance (for reviews, see references 5, 31, and 49).
We therefore wished to investigate the contributions of donor-derived and recipient-derived hematopoietic cells to the lymphohematopoietic reconstitution in our experimental model of MHC-disparate BMT using BALB/c mice (MHC class I molecules (Fig. 1B, left) . Thus, by the definition stated above, the recipients became complete chimeras with regard to the BM. It is instructive to note that B220 (CD45)-positive B cells and all cells of the myelomonocytic lineage, which includes Gr-1-positive granulocytes and CD11b-positive monocytes, were also found to be of donor origin (data not shown). By contrast, the reconstituted T-cell population, measured for the spleen, was found to be chimeric over the whole range of transplanted donor BMC. This chimerism represented a very stable balance, since 10-fold increases in the numbers of donor BMC resulted in only moderate shifts of the chimerism towards donor-derived T cells (Fig. 1C, top left) . This chimerism was not T-cell subset specific but applied likewise to CD4 T cells (Fig. 1C, center left) and to CD8 T cells, with a slight preponderance of donor-derived CD8 T cells (Fig.  1C, bottom left) . Specifically, there was no evidence for a selective amplification of recipient-derived CD8 T cells, as one would expect in case of an MHC class I-directed HvG response. The extrapolation predicts that unreasonable numbers of donor BMC would be needed to completely replace recipient-derived T cells. Thus, by the definition presented above, the recipients became mixed chimeras with regard to the T-cell pool. Such a difference in the chimeric state of different cell populations is referred to as a split chimerism. The origin of the recipient-derived T cells is an issue beyond the scope of this report. Regarding this question, it may be helpful to outline the current state of knowledge. Apparently, these cells cannot be derived from BM that is occupied by donor-derived hematopoietic cells. We have evidence that they are derived from radiation-resistant thymic progenitors, since their reconstitution can be prevented by thymectomy but not by in vivo depletion of peripheral T cells of either subset (not shown).
How does murine CMV infection interfere with this highly balanced system? In accordance with previous findings in models of MHC-compatible sex-matched (18) as well as sex-mismatched BMT (48) , murine CMV infection dramatically increased the death rates, but sufficiently high numbers of BMC protected against fatal CMV disease (Fig. 1A, right) . Compared with syngeneic BMT performed with BALB/c mice as 
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donors and recipients under otherwise identical conditions (18), the death rates were found to be slightly increased, suggesting a reduced efficacy of antiviral control as a result of the MHC class I mismatch. Fatal CMV disease is characterized by viral histopathology in almost all vital organs (34) and is associated with BM aplasia (29, 30). As we have shown recently, murine CMV infection inhibits the engraftment of low numbers of donor BMC, whereas high numbers of donor BMC support hematopoietic reconstitution by preventing hemopoietin deficiency of recipient stroma (48) . Accordingly, the BM of survivors was found to be repopulated with donor-derived hematopoietic cells (Fig. 1B, right) . Regarding T cells, the reconstitution of donor-derived T cells was inhibited by viral pathogenesis in the BM, but this effect was overcome by transplantation of 10 7 BMC. Again, there was no marked difference between the two T-cell subsets (Fig. 1C, right) . (34) , the lungs represent a major organ site of viral pathogenesis, latency, and recurrence (3, 25, 39) . Previous work has identified CD8 T cells as the principal antiviral effector cells controlling murine CMV in the lungs (18, 39) . Specifically, the model of syngeneic BMT with BALB/c donors and recipients had revealed a massive infiltration of the infected lungs preferentially by CD8 T cells, and the peak of this infiltration was found to correlate with the resolution of productive infection (18) . Here we have performed the corresponding experiments for the MHC-disparate setting (6 Gy, 10 7 BMC; corresponding to Fig. 1A, asterisk) with MHC class I L d -negative recipients (Fig. 2) . At the peak of the infiltration, CD8/CD4 ratios ranged between 0.7 and 2.1 in infected lungs, as opposed to 0.15 to 0.3 in uninfected lungs ( Fig. 2A and B) . In absolute terms, yields of T lymphocytes per lung were 1.2 ϫ 10 6 to 2.2 ϫ 10 6 and 0.1 ϫ 10 6 to 0.3 ϫ 10 6 in infected and uninfected lungs, respectively. This massive expansion of the pulmonary T-cell pool coincided with the resolution of lung infection (compare Fig. 2B and C) . In essence, the previous experience using syngeneic BMT was thus fully reproduced, with the notable difference that CD8 T-cell infiltration and resolution of lung infection were both delayed by about 1 week. In accordance with the slight increase in the death rates (Fig. 1A) , this finding indicated a lower efficacy of antiviral control in the MHCdisparate setting. However, the important finding is that the infiltrating cells did not fail to control the infection in the L d -negative lung parenchyma.
Control of murine CMV infection in the lungs correlates with infiltration of CD8 T cells. Among multiple organs infected by murine CMV in immunocompromised recipients
CD8 T cells in pulmonary infiltrates have the propensity to resolve murine CMV infection in various target tissues.
The coincidence between resolution of productive lung infection and the massive expansion of CD8 T cells in the lungs strongly suggested an antiviral function of these CD8 T cells, but correlative evidence is not a formal proof. We therefore directly tested the in vivo antiviral function of lung infiltrate cells by an approach of preemptive cytoimmunotherapy of murine CMV organ disease. Lymphocytes were isolated from pulmonary infiltrates at 5 weeks after BMT and infection and were adoptively transferred into immunocompromised and infected BALB/c indicator recipients. Protection against viral histopathology in the indicator recipients was monitored on day 14 after the cell transfer by two-color immunohistology of liver tissue, simultaneously detecting infected, IE1 protein-expressing liver cells and liver-infiltrating CD3ε-positive T lymphocytes (Fig. 3) . In the experimental group with no cells transferred (group A), foci of infection were frequent and caused a viral hepatitis, characterized by plaque-like tissue lesions with no prominent inflammatory infiltrates. Note the absence of nucleated cells in the center of the plaques, which indicates a cytocidal infection of the liver. The main target cell of murine CMV infection in the liver is the hepatocyte (Fig. A3* [ high resolution] shows details), while bile duct epithelial cells were usually not infected (not shown). As we anticipated from the design of the experiment, only few CD3ε-positive T lymphocytes were found in the liver parenchyma. Transfer of pulmonary infiltrate cells was associated with a cell dose-dependent infiltration of the recipient liver by CD3ε-positive T lymphocytes. This infiltration correlated with a decline in the number of infected cells and, as a consequence, with prevention of tissue destruction (groups B to D). Notably, infiltrating T cells were not randomly distributed in the liver parenchyma but were arranged in clusters, forming inflammatory foci that sequester the infected hepatocytes (Fig. 3C1 to C3 [overview] and C3* [details]). These inflammatory foci are reminiscent of foci formed in infected liver tissue by natural killer (NK) cells in another model of murine CMV hepatitis (45) , suggesting that trafficking of T cells and NK cells to the infected liver may be regulated similarly. After transfer of 10 6 cells, the livers were found to be free of virus, and there were no signs of histopathology except a remainder of T cells (Fig. 3, group D) . Quantitative immunohistology, compiling cell counts for three individual recipients per group and for representative areas of liver tissue sections, clearly documents the inverse relation between infection of liver tissue and infiltration by CD3ε-positive T cells (Fig. 4) .
The antiviral function of the pulmonary infiltrate cells was not restricted to the liver. Upon adoptive transfer, they limited virus replication, as measured by virus titers, in the spleen as well as in the lungs (Fig. 5) . The apparently higher efficacy of antiviral control in the spleen than in the lungs is not peculiar to pulmonary infiltrate-derived T cells but is a consistent finding made previously also with T cells derived from lymphoid tissues (reviewed in reference 22). In accordance with these earlier studies, the antiviral function was abolished by depletion of CD8 T cells but not of CD4 T cells (Fig. 5, right) . This result identified the antiviral effector cells in lung infiltrates as CD8 T cells. In conclusion, this set of experiments demonstrated the antiviral function of pulmonary CD8 T cells.
Recipient-derived CD8 T cells are preferentially recruited to the lungs. The chimerism of the T-cell pool detected in the spleen (Fig. 1C) raised the question of which T cells were recruited to the lungs. As the extremes, either donor-derived or recipient-derived T cells could be recruited selectively. We addressed this question by a cytofluorometric analysis of donor-recipient chimerism among CD8 T cells isolated from the infected lungs at the peak of infiltration. The pulmonary CD8 T-cell pool was found to be chimeric (Fig. 6 ), but notably, recipient-derived CD8 T cells were in this case preponderant. This finding indicated a preferential involvement of recipientderived CD8 T cells in the pulmonary immune response.
Absence of HvG-reactive CTL in lung infiltrates. One possible reason for a selective amplification of recipient-derived T cells in the infected lungs could be an HvG response directed against the L d molecule expressed by the infiltrating donorderived cells. Such a response could be supported by the cytokine milieu generated during the CMV-induced inflammatory process. We have investigated this possibility by ex vivo testing of L d -specific CTL activity in pulmonary infiltrates at the peak of the infiltration. Pulmonary T lymphocytes did not lyse L d -expressing P815 target cells (Fig. 7A) . Thus, lung infiltrates did not include HvG-reactive, ex vivo cytolytic effector cells. While engagement of the TCR-CD3 complex suffices for eliciting the cytolytic effector function of mature CTL, less mature CTL precursors can be triggered to exert cytolytic activity only if target cells express B7-1 (CD80) for costimulatory signalling by B7-CD28 interaction (1, 2). Since P815 mastocytoma cells do not express B7, CTL precursors were not detected by the assay used. Donor-derived activated B and T cells as well as monocytes in the infiltrates are potential targets for an HvG reactivity of B7-dependent effector cells because they express L d as well as B7. Notably, however, provision of B7 by using the transfectant P815-B7 as the target cell in the cytolytic assay did not enable detection of B7-dependent L dspecific effector cells in the lung infiltrates (Fig. 7B) . Finally, an HvG reactivity operating via Fas-Fas ligand interaction inducing apoptosis (43) was excluded by the use of transfectant P815-Fas as the target cell (Fig. 7C) . These negative results raised the question of whether CTL activity had developed at all within lung infiltrates. Redirected lysis of Fc receptor-expressing P815 target cells armed with antibody specific for TCR or CD3 (24) is a method for detecting all CTL regardless of their antigen specificity. The TCR ␣/␤ redirected lysis assay indeed revealed a very strong CTL activity within lung infiltrates (Fig. 7D ). In conclusion, lung infiltrates contained CTL, but HvG-reactive CTL were not present in detectable numbers. We therefore concluded that the amplification of recipient-derived T cells resulted from their participation in the antiviral response.
Sorted donor-derived and recipient-derived pulmonary CD8 T cells are both cytolytically active. For testing the functional properties of the two sets of CD8 T cells, they had to be separated and purified preparatively. To this end, CD8 T cells among pulmonary infiltrate lymphocytes were positively enriched to Ͼ95% purity by immunomagnetic selection. The (Fig. 8A) . The cytolytic activity of the sorted sets of CD8 T cells was tested by the TCR ␣/␤ redirected lysis assay (Fig. 8B) . Compared with the presorting cytolytic activity of the chimeric CD8 T-cell population (Fig. 8B, left panel) , there was some loss of activity by the sorting procedure, as one would expect, but the sets of CD8 T cells showed comparable activities (Fig. 8B, right (Fig. 7) , a GvH complication did not occur in L d -positive indicator mice. Antiviral activity in liver and spleen was monitored by ISH detecting productively infected cells characterized by viral DNA accumulated in an intranuclear inclusion body (Fig. 9) . In the absence of protecting cells, the degrees of infection and histopathology were comparable in both genotypes of indicator mice (Fig. 9, top row) . Notably, recipientderived pulmonary CD8 T cells protected indicator tissues of either genotype with similar efficacies (Fig. 9, center row) . By contrast, donor-derived pulmonary CD8 T cells virtually failed to protect the recipient-matched indicator tissues (Fig. 9 , bottom row), even though they were effectual in donor-matched indicator tissues. It should be noted that this failure was not absolute, but that higher numbers of donor-derived CD8 T cells were needed to control murine CMV also in the L d -negative recipient (not shown).
These findings were substantiated by counting the infected cells for a representative area of liver and spleen tissue sections and by documenting the variance for three individually tested indicator mice per experimental group (Fig. 10) . The quantitative data gave us a more qualified view. In principle, CD8 T cells of either MHC genotype showed a preference for the MHC-matched indicator tissues, but this preference was far more pronounced for the L d -positive donor-derived CD8 T cells.
Since the infected tissue cells in the mixed BMT chimeras are of recipient genotype, we conclude that control of murine CMV infection in their lungs and other organs was predominantly but not exclusively a function of recipient-derived, i.e., of endogenously reconstituted, antiviral CD8 T cells. As a consequence, we propose that the establishment of a mixed chimerism after BMT gives an advantage to the BMT recipient with respect to the control of CMV infection.
DISCUSSION
Despite routine preemptive antiviral chemotherapy, human CMV infection continues to be a major complication in patients receiving BMT. Even though the case-fatality rate of CMV disease, pneumonia in particular, is high also in patients receiving syngeneic BMT or a stem cell autograft, it is established clinical experience that minor and especially major histocompatibility antigen disparities are associated with an increased incidence of severe CMV disease (reviewed in reference 10). A pathogenic link between GvH disease and CMV infection is indicated by clinical data (10) and by murine models involving transfer of mature, immunoreactive allogeneic T cells into infected recipients (8, 9, 13) . While CMV infection may promote GvH disease by inducing inflammatory cytokines or by altering the expression of MHC molecules and of cell adhesion molecules, recent work by Soderberg-Naucler et al. has provided evidence also for a cooperative effect in the opposite direction, namely for the reactivation of latent CMV by allogeneic stimulation (46) . If donor and recipient differ at an MHC locus, allogeneic stimulation can theoretically occur in either direction, resulting in simultaneous GvH and HvG responses. It is therefore difficult to dissect the contributions of GvH and HvG reactions to CMV pathogenesis in transplantation chimeras. This problem has prompted us to develop the murine model described herein, using a pair of mouse strains, BALB/c and BALB/c-H -2 dm2 , that differ by the presence and absence of the MHC class I molecule L d , respectively. Depending on the choice of donor and recipient for the experimental BMT, GvH-and HvG-related complications can thus be analyzed separately. The present study was focused on the HvG version of this model, with the aim to characterize the influence of a singular MHC class I disparity on the course of murine CMV disease in the specific context of the reconstitution of antiviral immunity after BMT.
One notable finding from the data is the absence of an immunological HvG response in recipients after incomplete lymphohematoablation followed by MHC class-I disparate BMT. Specifically, the donor BMC mediated protection against death and repopulated the recipient with all hematopoietic lineages, including ␣/␤ T lymphocytes. However, over a wide range of experimental conditions, residual recipient T lymphopoiesis led to a chimeric T-cell population in the survivors. Since mixed chimerism can develop only after incomplete lymphohematoablation of the BMT recipient, one might ask whether the chosen setting of experimental BMT is appropriate as a model for clinical BMT. We think it is, because mixed chimerism is reportedly a frequent feature after clinical BMT, in particular after transplantation of T-cell-depleted BMC (15, 19, 28, 33) . Interestingly, recent clinical data suggest a survival advantage of mixed chimeric patients (19) .
In the model system described here, evidence against an immunological HvG response was provided by the long-term coexistence of donor-derived and recipient-derived T cells and by the apparent absence of L d -specific ex vivo CTL in the pulmonary infiltrates. While the association between mixed chimerism and donor-MHC specific transplantation tolerance had been known since the pioneering work of Billingham et al. (4) , the molecular mechanisms leading to transplantation tolerance had remained enigmatic. Only recently, the expression of Fas ligand (CD95L) on transplanted BMC was found to be essential for tolerance induction, relating tolerance to apoptotic deletion of graft-reactive cells (12) .
An interplay between transplantation tolerance and viruses is an interesting possibility. Since CMV is a virus of known pathogenic relevance in BMT recipients, it is a primary candidate for such an interplay. The data presented herein show that murine CMV infection can alter the chimeric balance to the disfavor of the donor-derived repopulation, and this could reduce the tolerogenic donor cell dose. However, the murine model presented here did not provide evidence for CMV being a trigger of an acute HvG response. In conclusion, residual recipient T lymphopoiesis does not result in rejection of the BM graft.
What, then, are the consequences of T-cell chimerism for the control of CMV? Specifically, is mixed chimerism beneficial or deleterious for the infected recipient? We infer from the data that residual recipient T lymphopoiesis can indeed be beneficial by controlling CMV infection. A vital role for donor BMC in the hematopoietic repopulation became obvious from the dose-dependent improvement of the survival rates in both groups of recipients, uninfected as well as infected. Clearly, hematopoietic donor cells are of immediate need to overcome the BM aplasia caused by the hematoablative treatment in that they repopulate the recipient BM with all hematopoietic cell lineages. In addition, hematopoietic donor cells protect the recipient BM stroma against CMV-induced hemopoietin downregulation by an undefined mechanism that is unrelated to control of infection (48) . Without these basic protective functions of the transplanted donor BMC, neither donor-derived nor recipient-derived immunocompetent T cells would be reconstituted. A significant participation of recipient-derived CD8 T cells in the antiviral response was first indicated by their preferential expansion in the infected lungs. Firm evidence was in this model, was missing in recipient tissue. The phenomenon is likely to be related to the known role of L d as the prevailing peptide presenter molecule in the H-2 d haplotype (6, 32), a feature that has been explained by low loading of L d with self peptides providing accessible binding sites for foreign peptides (26) . Accordingly, the immunodominant IE1 nonapeptide of murine CMV is presented by L d (38) . Recent work has shown that IE1-specific CTL dominate the pulmonary CTL response to murine CMV after syngeneic BMT performed with BALB/c mice as donors and recipients, even though this dominance was relative rather than absolute (18) . The data shown here do indicate that peptides presented by L d , but not necessarily only the immunodominant IE1 peptide, account for a biologically relevant part of the CD8 T-cell response to murine CMV in the H-2 d haplotype. Since the tissue cells in the mixed chimeras did not express L d , the focus of the donor-derived CD8 T cells to L d implies that they have acquired immunodominance from an intrinsic viral peptide presentation by L d within the population of donor cells. This is surprising, because productive murine CMV infection occurs primarily in stromal and parenchymal tissue cells (34) . We must now propose that donor-derived lung infiltrate cells included a sufficient number of infected cells presenting viral peptides processed from endogenously synthesized proteins, or that they presented antigenic viral peptides generated by exogenous loading of the MHC class I pathway of antigen presentation (for a review, see reference 20) with viral proteins derived from the infected L d -negative lung tissue cells. Work is in progress to identify and quantitate the antigenic viral peptides processed in the different compartments of the mixed chimeric lungs.
In conclusion, the mixed chimera model has shown that an MHC preference leading to an immunodominant antiviral response within the donor-derived cell population can prevent the donor CD8 T cells from protecting recipient tissues. In such a scenario, BMT recipients depend on the otherwise subdominant immune response that is provided by residual own lymphopoietic reconstitution. Since MHC-governed immunodominance of antigens is not the exception, our results may apply to other mixed chimeric systems as well. We therefore propose that establishment of a T-cell chimerism after MHC-disparate BMT is beneficial with respect to the control of infections.
